Roche announced CE marking for its cobas Eplex respiratory pathogen panel 3 (RP3), bringing a molecular test that simultaneously detects and differentiates up to 25 respiratory targets. The assay covers both viral and bacterial pathogens including SARS-CoV-2, influenza, Bordetella pertussis, and respiratory syncytial virus, and is intended for use in countries accepting the CE designation. Roche said the panel requires less than one minute of hands-on time to start and runs on the cobas Eplex system with automated result reporting and external control tracking and monitoring. The product also includes updated inclusivity for influenza and SARS-CoV-2 variants as well as flexible syndromic testing that allows laboratories to customize up to five panels based on local prevalence. The approval expands Roche’s automated diagnostics footprint and supports faster, multiplexed decision-making in respiratory care settings where pathogen identification can affect treatment pathways.